Join the UM Ventures, Baltimore team and industry experts at 2 p.m. Feb. 12 to gain valuable knowledge about navigating the regulatory landscape. Whether you're involved in drug development or diagnostics, this session will equip you with the strategies needed to succeed.
Michael Kates, PhD, will share his knowledge gained from 12-plus years of contract development and manufacturing organization experience and cover the general investigational new drug (IND) and regulatory process for small molecule drug candidates and biologics.
Brad Young, PhD, MBA, an alum of the University of Maryland School of Medicine, will share his biotechnology business expertise and real-world examples of regulatory strategies for companion and complementary diagnostics.
Guest Speakers
Brad Young, PhD, MBA
Owner and Senior Principal
B.A.Y. Biotech Consulting
Entrepreneur-in-Residence
University of Maryland, Baltimore
Michael Kates, PhD
Vice President, Integrated IND/NDA Program Development
DavosPharma